Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Study of Jintrolong in Children with GHD
NCT02314676Phase 4Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of peg-somatropin in growth hormone deficiency (GHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Actual height compared with mean height and SD of population at 26 weeks. Status: unknown.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02314676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314676.